ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Renal"

  • Abstract Number: 1387 • ACR Convergence 2020

    Should Systemic Sclerosis Patients with Low Bicarbonate Have Replacement to Prevent Renal Dysfunction?

    Megan Meier1, Jacob Stever2, Josephine Wright1, Tracy Frech3, Greg Stoddard1 and Benjamin Tingey1, 1University of Utah, Salt Lake City, 2University of Utah, SANDY, 3University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT

    Background/Purpose: Scleroderma renal crisis (SRC) is a well-characterized condition in patients with systemic sclerosis, but systemic sclerosis patients frequently develop chronic kidney disease (CKD) without…
  • Abstract Number: 1425 • ACR Convergence 2020

    Reduced Risk of Cardiovascular Diseases Events with Renal Transplantation in Granulomatosis with Polyangiitis in the United States: Data from the US Renal Data System

    Zachary Wallace1, April Jorge2, Xiaoqing Fu3, Yuqing Zhang4 and Hyon Choi5, 1Massachusetts General Hospital, Newton, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Boston, 4Massachusetts General Hospital, Quincy, MA, 5Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA

    Background/Purpose: Granulomatosis with polyangiitis (GPA) is a common cause of glomerulonephritis and leads to end-stage renal disease (ESRD) in approximately 25% of patients. Both GPA…
  • Abstract Number: 1512 • ACR Convergence 2020

    Trajectory Analysis of Repeat Renal Biopsies Identified Previous Endocapillary Proliferation as Predictor of Damage and End Stage Renal Disease in Pure Membranous Lupus Nephritis

    Andrea Fava1, Avi Rosenberg2, Serena Bagnasco2, Paride Fenaroli2, Jessica Li1, Jose Monroy-Trujillo2, Derek Fine2 and Michelle Petri3, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University, Baltimore, 3Johns Hopkins University School of Medicine, Baltimore

    Background/Purpose: . Pure membranous (class V) lupus nephritis is considered a less aggressive phenotype, but renal fibrosis and chronic kidney disease may develop. Whether this…
  • Abstract Number: 1514 • ACR Convergence 2020

    The Impact of Renal Transplantation on Cardiovascular Events Among Patients with End-State Kidney Disease Due to Lupus Nephritis: A Nationwide Cohort Study

    April Jorge1, Xiaoqing Fu2, Yuqing Zhang3, Hyon Choi4 and Zachary Wallace5, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, 3Massachusetts General Hospital, Harvard Medical School, Boston, 4Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, 5Harvard Medical School, Boston

    Background/Purpose:A major complication of systemic lupus erythematosus (SLE) is the progression of lupus nephritis (LN) to end-stage kidney disease (ESKD). Both SLE and ESKD are…
  • Abstract Number: 1515 • ACR Convergence 2020

    Renal Responder Status and Associated Clinical Variables in the Lupus Accelerating Medicines Partnership Cohort

    Philip Carlucci1, Andrea Fava2, Kristina Deonaraine1, Jessica Li3, David Wofsy4, Judith James5, Chaim Putterman6, Betty Diamond7, Derek Fine8, Jose Monroy-Trujillo8, Kristin Haag8, William Apruzzese9, H. Michael Belmont10, Peter Izmirly11, Sean Connery12, Fernanda Payan-Schober12, Richard Furie13, Celine Berthier14, Maria Dall'Era15, Kerry Cho16, Diane Kamen17, Kenneth Kalunian18, The Accelerating Medicines Partnership in SLE Network19, Michelle Petri20 and Jill Buyon21, 1New York University School of Medicine, New York, 2Johns Hopkins, Baltimore, 3Johns Hopkins University, Baltimore, MD, 4University of California San Francisco, San Francisco, CA, 5Oklahoma Medical Research Foundation, Oklahoma City, 6Albert Einstein College of Medicine, Bronx, NY, 7Northwell Health, Hartford, 8Johns Hopkins University, Baltimore, 9., Boston, 10NYU School of Medicine, New York, NY, 11Department of Medicine, New York University School of Medicine, New York, NY, 12Texas Tech University Health Sciences Center, Lubbock, 13Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 14University of Michigan, Ann Arbor, 15Division of Rheumatology, University of California, San Francisco, CA, 16University of California San Francisco, San Francisco, 17Medical University of South Carolina, Charleston, SC, 18School of Health Sciences, University of California, La Jolla, 19Multiple Institutions, Multiple Cities, 20Johns Hopkins University School of Medicine, Baltimore, 21Department of Medicine, NYU School of Medicine, New York, NY

    Background/Purpose: Poor therapeutic response rates contribute to the increased morbidity and mortality associated with lupus nephritis. Early identification of patients likely to respond is crucial…
  • Abstract Number: 1516 • ACR Convergence 2020

    The Value of Renal Biopsy at Lower Levels of Proteinuria in Patients Enrolled in the Lupus Accelerating Medicines Partnership

    Philip Carlucci1, Kristina Deonaraine1, Andrea Fava2, Jessica Li3, David Wofsy4, Judith James5, Chaim Putterman6, Betty Diamond7, Derek Fine8, Jose Monroy-Trujillo8, Kristin Haag8, William Apruzzese9, H. Michael Belmont10, Peter Izmirly11, Sean Connery12, Fernanda Payan-Schober12, Richard Furie13, Celine Berthier14, Maria Dall'Era15, Kerry Cho16, Diane Kamen17, Kenneth Kalunian18, The Accelerating Medicines Partnership in SLE Network19, Michelle Petri20 and Jill Buyon21, 1New York University School of Medicine, New York, 2Johns Hopkins, Baltimore, 3Johns Hopkins University, Baltimore, MD, 4University of California San Francisco, San Francisco, CA, 5Oklahoma Medical Research Foundation, Oklahoma City, 6Albert Einstein College of Medicine, Bronx, NY, 7Northwell Health, Hartford, 8Johns Hopkins University, Baltimore, 9., Boston, 10NYU School of Medicine, New York, NY, 11Department of Medicine, New York University School of Medicine, New York, NY, 12Texas Tech University Health Sciences Center, Lubbock, 13Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 14University of Michigan, Ann Arbor, 15Division of Rheumatology, University of California, San Francisco, CA, 16University of California San Francisco, San Francisco, 17Medical University of South Carolina, Charleston, SC, 18School of Health Sciences, University of California, La Jolla, 19Multiple Institutions, Multiple Cities, 20Johns Hopkins University School of Medicine, Baltimore, 21Department of Medicine, NYU School of Medicine, New York, NY

    Background/Purpose: Lupus nephritis continues to be the complication with the highest standardized mortality ratio in Systemic Lupus Erythematosus (SLE), and a late diagnosis associates with…
  • Abstract Number: 1626 • ACR Convergence 2020

    Long-Term Follow-Up of Renal Transplantation Due to Lupus Nephritis. Single Universitary Center Experience

    Lara Sanchez-Bilbao1, Marina De Cos-Gomez2, Inigo Gonzalez-Mazon3, David Martinez-Lopez4, Juan Carlos Ruiz-San Millan2, Miguel Ángel González-Gay5 and Ricardo Blanco1, 1Hospital Universitario Marques de Valdecilla, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 3Hospital Universitario Marques de Valdecilla, Bezana, Spain, 4Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, 5Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE). Approximately 10-20% of LN develop end stage renal disease (ESRD) and need…
  • Abstract Number: 1672 • ACR Convergence 2020

    Renal Activity Index for Lupus Nephritis Distinguishes Active Renal Disease Among Childhood Systemic Lupus Erythematosus Patients

    Najla Aljaberi1, Arjun Mathur2, Steffy Jose3, Theresa Hennard4, Angela Merritt1, Qing Ma5, James Rose5, Rashmi Sahay6, Chunyan Liu6, Scott Wenderfer7 and Hermine I Brunner8, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, 3Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Divison of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, 6Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, 7Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, 8PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Renal involvement in childhood-onset systemic lupus erythematosus (cSLE) is a major cause of morbidity and mortality. Current tools to identify lupus nephritis (LN) fall…
  • Abstract Number: 0232 • ACR Convergence 2020

    Safety and Effectiveness of Tocilizumab in Patients with Renal Insufficiency in the Non-interventional Study ICHIBAN

    Christof Specker1, Martin Aringer2, Gerd Burmester3, Johannes Gerlach4, Michael Hofmann5, Herbert Kellner6, Frank Moosig7, Hans-Peter Tony8 and Gerhard Fliedner9, 1Clinic Essen-Mitte, Essen, Germany, 2Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, Dresden, Germany, 3Charité University Hospital Berlin, Berlin, Germany, 4Roche Pharma AG, Grenzach-Wyhlen, Germany, 5Chugai, Frankfurt am Main, Germany, 6Rheumatology and Gastroenterology Specialty Practice, Munich, Germany, 7Rheumatology Center Schleswig-Holstein Middle, Neumünster, Germany, 8Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany, 9Rheumatology Practice, Onsabrück, Germany

    Background/Purpose: RA increases a patient’s systemic inflammatory burden, which has been associated with development of chronic kidney disease (CKD), especially in patients with comorbid hypertension,…
  • Abstract Number: 1793 • ACR Convergence 2020

    Safety of Obtaining Research Tissue During Clinically Indicated Kidney Biopsies: Data from the Lupus Accelerating Medicines Partnership

    Kristina Deonaraine1, Philip Carlucci1, Andrea Fava2, Jessica Li3, David Wofsy4, Judith James5, Chaim Putterman6, Betty Diamond7, Derek Fine8, Jose Monroy-Trujillo8, Kristin Haag8, William Apruzzese9, H. Michael Belmont10, Peter Izmirly11, Sean Connery12, Fernanda Payan-Schober12, Richard Furie13, Celine Berthier14, Maria Dall'Era15, Kerry Cho16, Diane Kamen17, Kenneth Kalunian18, The Accelerating Medicines Partnership in SLE Network19, Michelle Petri20 and Jill Buyon21, 1New York University School of Medicine, New York, 2Johns Hopkins, Baltimore, 3Johns Hopkins University, Baltimore, MD, 4University of California San Francisco, San Francisco, CA, 5Oklahoma Medical Research Foundation, Oklahoma City, 6Albert Einstein College of Medicine, Bronx, NY, 7Northwell Health, Hartford, 8Johns Hopkins University, Baltimore, 9., Boston, 10NYU School of Medicine, New York, NY, 11Department of Medicine, New York University School of Medicine, New York, NY, 12Texas Tech University Health Sciences Center, Lubbock, 13Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 14University of Michigan, Ann Arbor, 15Division of Rheumatology, University of California, San Francisco, CA, 16University of California San Francisco, San Francisco, 17Medical University of South Carolina, Charleston, SC, 18School of Health Sciences, University of California, La Jolla, 19Multiple Institutions, Multiple Cities, 20Johns Hopkins University School of Medicine, Baltimore, 21New York University, New York, NY

    Background/Purpose: Lupus nephritis (LN) is a major complication of systemic lupus erythematous (SLE) and affects ~60% of patients during the course of their disease, leading…
  • Abstract Number: 0261 • ACR Convergence 2020

    Predictors of Future Repeat Renal Biopsies in Patients with Lupus Nephritis and Influence of Repeat Biopsy in Flare Management: A Retrospective Study

    Rosalba Santana-Flores1, Anitha Ramu1, Hana Rajevac2 and Belinda Jim3, 1Jacobi Medical Center at Albert Einstein College of Medicine, BRONX, NY, 2James J Peters Medical Center, NEW YORK, NY, 3Jacobi Medical Center at Albert Einstein College of Medicine, New Hyde Park, NY

    Background/Purpose: Repeat renal biopsies are considered in patients with Lupus Nephritis (LN) flares or with failure of response to treatment. The influence of repeat renal…
  • Abstract Number: 1796 • ACR Convergence 2020

    A Panel of Urinary Proteins Predicts Active Lupus Nephritis and Response to Rituximab Treatment

    Jennifer Davies1, Emil Carlsson1, Angela Midgley1, Eve Smith1, Ian Bruce2, Michael Beresford1 and Christian Hedrich3, 1Department of Women's and Children's Health, Institute of Life Course and Medical Sciences, Liverpool, England, United Kingdom, 2Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 3University of Liverpool, Liverpool, United Kingdom

    Background/Purpose: Approximately 30% of patients with adult-onset systemic lupus erythematosus (SLE) develop lupus nephritis (LN). Presence and/or severity of LN are currently assessed by renal…
  • Abstract Number: 0432 • ACR Convergence 2020

    The Effect on Renal Function of the Complement C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis

    Peter Merkel1, Pirow Bekker2, Huibin Yue2, Catherine Kelleher2, Thomas Schall2 and David Jayne3, 1University of Pennsylvania, Philadelphia, PA, 2ChemoCentryx, Mountain View, CA, 3Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom

    Background/Purpose: Avacopan, a novel, orally-administered selective antagonist of C5aR, was recently evaluated in a pivotal Phase 3 randomized clinical trial where its use in patients…
  • Abstract Number: 1837 • ACR Convergence 2020

    Clinical Outcomes in Lupus Nephritis by Renal Response Status: A Retrospective Analysis of the Hopkins Lupus Cohort

    Michelle Petri1, Qinggong Fu2, Yulia Green3, Anuradha Madan4, Daniel Goldman5 and Selin Cooper-Blenkinsopp6, 1Johns Hopkins University School of Medicine, Baltimore, 2GlaxoSmithKline, Upper Providence, 3GlaxoSmithKline, Uxbridge, 4GlaxoSmithKline, Collegeville, 5Johns Hopkins University School of Medicine, Timonium, MD, 6GlaxoSmithKline, Stevenage, United Kingdom

    Background/Purpose: A retrospective analysis of the Hopkins Lupus Cohort (a prospective, longitudinal study of patients [pts] with systemic lupus erythematosus) reported that renal response (complete/partial/none)…
  • Abstract Number: 0523 • ACR Convergence 2020

    Characterization of Antiphospholipid Antibody-Associated Nephropathy: An International Survey of Renal Pathology Society Members

    Medha Barbhaiya1, Doruk Erkan2, Stephane Zuily3, Tektonidou Maria4 and Surya Seshan5, 1Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Nancy Academic Hospital, Vandoeuvre-l�Nancy, France, 4National and Kapodistrian University of Athens, Athens, Greece, 5Weill Cornell Medical College, New York, NY

    Background/Purpose: Antiphospholipid antibody (aPL)-associated nephropathy (aPL-N) is recognized as a distinct complication of APS. However, it remains unclear whether pathologists worldwide use uniform diagnostic criteria…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology